| 摘要 |
Controlled release and delayed release formulations which are adapted or intended for oral administration and which contain paroxetine hydrochloride, such as a formulation which is a system for the controlled and delayed release of paroxetine hydrochloride, having (a) a deposit-core comprising 28.61 mg paroxetine hydrochloride, 18.7 mg methocel K4M, 79.14 mg lactose monohydrate, 2.50 mg polyvinylpyrrolidone, 1.25 mg magnesium stearate, and 0.50 mg Syloid 244, and (b) a support-platform applied to said deposit-core comprising 15.04 mg Compritol 888, 30.50 mg lactose monohydrate, 4.00 mg polyvinylpyrrolidone, 0.80 mg magnesium stearate, 29.32 mg methocel E5, 0.32 mg Syloid 244, and 0.02 mg iron oxide; and (c) an enteric coating comprising 13.27 mg Eudragit, 3.31 mg talc, and 1.33 mg triethyl citrate, may be used to treat a variety of disorders including depression. |
